Dagibatran carries reduced fracture risk compared with warfarin
Among patients with nonvalvular atrial fibrillation, study data show the use of dabigatran rather than warfarin was associated with a lower risk of osteoporotic fracture.
Source: Medical Photo NHS Lothian / Science Photo Library
Warfarin has been associated with increased risk of osteoporotic fractures but it has been suggested that dabigatran, which has a different mode of action, might not carry the same risk.
To explore, researchers studied data from a Hong Kong hospital taken from patients with nonvalvular atrial fibrillation, including 3,268 new dabigatran users which were matched to 4,884 new warfarin users.
During a mean follow-up of 501 days, the risk of osteoporotic fracture was significantly lower among dabigatran users than warfarin users (0.7 vs 1.1 per 100 person-years). However, the association with lower risk was only statistically significant for patients with a history of fractures and/or falls (1.6 vs 3.6 per 100 person-years) but not for those without (0.6 vs 0.7 per 100 person years).
Reporting in JAMA (online, 21 March 2017), the researchers suggest that patients could be screened for osteoporotic risk to inform anticoagulant choice, but the findings warrant further investigation.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202567
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com